Magellan Rx Report
Our award-winning report provides insights on the industry’s most innovative and groundbreaking managed care solutions for some of the most complex areas of healthcare.
Spring 2023
Fall 2022
- Rheumatoid Arthritis
- Metastatic Bladder Cancer
- Gene Therapy
- Age-Related Macular Degeneration and Diabetic Macular Edema
- Hereditary Transthyretin Amyloidosis
Summer 2022
- Biomarker testing
- Gene Therapy
- Chronic Heart Failure
- CAR-T Update
- Psoriasis: Current treatment landscape and management
Spring 2022
- Sleep Disorders
- Multiple Sclerosis
- Parkinson’s Disease
- Biosimilar Update
- Gout Management
- COVID-19 Update
- Cervical Cancer
- Pipeline
Fall 2021
- Atopic Dermatitis
- Lupus and Lupus Nephritis
- Biosimilar Update and Pipeline
- Alzheimer’s Disease
- Chronic Kidney Disease
- Magellan Capability Insight
- Dry Eye Disease
Summer 2021
-
Amyotrophic Lateral Sclerosis
-
Gene Therapies for Rare Diseases
-
HER2+ Metastatic Breast Cancer
-
HIV Update
-
CAR-T Update
-
COVID-19 and Oncology Care
-
Pipeline
Spring 2021
- COVID-19: Impact on Delivery of Care
- Wet AMD
- Mental Health Update
- Multiple Myeloma
- Rare Neuromuscular Diseases
- IV Iron
- Pipeline
Fall 2020
- Hemophilia treatment options and gene therapy
- Muscular dystrophy and spinal muscular atrophy
- COVID-19 pipeline update
- Biosimilar landscape and impact
Summer 2020
- Sickle Cell Disease: Clinical and Management Update
- Peanut Allergy: Advances in Treatment
- Asthma Update: Current Guidelines and Treatment Options
- Oncology Biosimilars: Update and Payer Considerations
- Managing Obesity: Developing a Successful Weight-Management Program
Spring 2020
-
Autoimmune Diseases
-
Multiple Sclerosis
-
Gene Therapy
- MRx Navigate
-
Rare Liver Disease Update
Fall 2019
- Measuring Total Cost of Care
- Epilepsy: Advances in Treatment and Management
- Precision Medicine in Oncology
- Artificial Intelligence: Advances in Healthcare Innovation
- Pipeline Drug List
Summer 2019
- Strategies for Staying Ahead of Specialty Drug Trends
- Medical Oncology Biosimilars
- Psoriasis Update
- Leveraging Technology to Improve Medication Adherence and Optimize Health Outcomes
- Pipeline Drug List
NTRK Spotlight
- NTRK Gene Fusions
- Incidence of NTRK Gene Fusions
- Inhibitors and Pipeline
- Gene Fusion Testing
- NGS Testing: DNA-Based and RNA-Based
Spring 2019
- Migraine Management
- Trends in Oncology Management
- Digital Therapeutics
- Rare Disease Management
- Pharmacogenetics in Managed Care
Fall 2018
- Multiple Sclerosis
- PI3K Inhibitors Pipeline
- Multiple Myeloma Treatment
- PARP Inhibitors in Ovarian Cancer
- Opioid Use Disorder
Summer 2018
- Biosimilars
- High-Cost Therapy Payment Strategies
- Cystic Fibrosis
- Asthma
- Human Immunodeficiency Virus
Spring 2018
- Orphan Diseases
- Alzheimer’s Disease
- The Opioid Crisis
- Migraine Pipeline & Treatment
Fall 2017
- CAR-T and Gene Therapies
- Opioid-Induced Constipation
- Osteoporosis in the Managed Care Setting
- Star Ratings and Quality Improvement
- Variable Fee Schedule Reimbursement
Summer 2017
- Migraine Treatment
- PD-1 and PD-L1 Inhibitors
- Computerized Cognitive Behavioral Therapy
- Hemophilia
Spring 2017
- Personalizing Medicine to Transition Oncology Care
- Type 2 Diabetes
- Inflammatory Conditions
- Immune Globulin
Summer 2016
- Biosimilars
- Multiple Myeloma
- Medical Drug Management Strategies
- Long-Acting Injectable Antipsychotics
- Value Based PBM
Spring 2016
- PCSK9 Inhibitors and Hypercholesterolemia
- Real-World Studies
- AMD
- Medical Pharmacy Expenditures
- PD-1 Inhibitors
Fall 2015
- Pulmonary Arterial Hypertension and Pulmonary Fibrosis
- Treating Opioid Dependency
- ACOs
- Evaluating AMD
- Improving Star Ratings
Summer 2015
- Hemophilia
- PCMH Model
- Site of Care
- Medical Pharmacy Solutions
- Medicare Part D Regulations
Spring 2015
- PCSK9 Inhibitors
- Next Generation Sequencing
- Hepatitis C
- Opioid Dependency
- Multiple Sclerosis
Fall 2014
- Hepatitis C Virus
- Optimizing HAE
- CLL Treatment
- Metastatic Melanoma
- Infliximab Site of Care
Summer 2014
- Heart Failure Management
- Immune Globulin Therapy
- Star Ratings
- Quality Improvement in Diabetes
Spring 2014
- Specialty Management Solutions
- Prostate Cancer
- Biosimilars
- Immune Globulin
- Renal Cell Carcinoma
Fall 2013
- A New Era of Oncology Management
- CML
- Oral Oncology
- Understanding Hemophilia
Summer 2013
- New Generation of Specialty Management
- Gaucher Disease
- Managing Hereditary Angiodema
- Neurotoxins
- Antiplatelet Therapy for ACS
Spring 2013
- Specialty Management
- Immune Globulin Therapy
- Reproductive Therapies
- Prostate Cancer
- Adherence in Patients with HIV
Fall 2012
- Specialty Management Solutions
- Innovations in Prostate Cancer Treatment
- Inside a Pioneer ACO
- Future Impact of Biosimilars
- Specialty Trends Update
Summer 2012
- CMS Star Ratings
- Transitioning to the Pioneer ACO Model
- Benefits of Motivational Interviewing
- The PPACA Contraception Mandate
- Pediatric Buprenorphine Exposure
Spring 2012
- Managed Care Solutions
- Cost-Effectiveness of Oral Anticoagulants
- CMS Stars
- New MLR Requirements
- Transitioning to Accountable Care
Fall 2011
- Managed Care Solutions
- GLP-1 Agonists
- CMS Star Ratings
- The Clinical Benefits of Prior Authorizations
- Navigating Accountable Care Organizations
Spring 2011
- Diabetes Management
- Asthma Controller Medication
- Type 2 Diabetes
- Improving Your Star Ratings
- Effects of Medication Reconciliation on Readmissions